rahul kapur (@dockapur) profile picture

Physician ,hospitalist ,tweets are not medical advice and only my opinions

Overland Park, KS
Joined April 2009
Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)Photo by rahul kapur (@dockapur)
rahul kapur retweeted
Howdy folks. I’m not running for office in 2028. I’ll keep speaking out and supporting others as I always do. Thanks for all the encouragement though. Means a lot.
68
45
12
1,525
53,400
rahul kapur retweeted
Thinking ahead to 2028, does anyone know any strong Dem contender against Eric Schmitt in Missouri? Someone with deep ties to the state, maybe military service, has won statewide before and outperformed the national ticket in a tough year?
38
27
7
558
89,285
ProTip: RETA elevates GDF15, prior was 600….
36
12
3
117
134,665
rahul kapur retweeted
Must be a lot of women in that stadium with exposed shoulders because our kicking game seems really off.
34
91
5
2,477
64,509
rahul kapur retweeted
Ozempic melts your muscle, they said. Meanwhile the SELECT trial found a 20% drop in heart attacks, strokes, and cardiovascular death in over 17,000 people with obesity who didn't even have diabetes. Kevin Hall's data shows the lean mass lost on these drugs sits at the same 20 to 30% ratio you'd see with keto, fasting, or bariatric surgery. Not unique. Not dangerous. The headline that got the clicks wasn't the one that saves lives.
4
9
54
4,276
The University of Arkansas just launched the 1st U.S. based injectable BPC-157 Randomized Controlled Trial for tissue healing. They’re studying post-rotator cuff surgery healing through objective measures like strength testing, MRI, and range of motion. Also patient reported questionnaires on recovery (PROMs). This is what the science community and physicians needed. Enrollment starts Early 2027. First data likely to be seen Early 2028. I will keep you updated. clinicaltrials.gov/study/NCT… #bpc #bpc157 #peptide #peptides #science #research
59
122
45
1,123
984,158
rahul kapur retweeted
Part of becoming an adult is realizing you have to abuse stimulants
107
1,277
71
20,583
628,288
rahul kapur retweeted
I’m a Mizzou fan. But I went to school out east and came home. Diana taught there though while we lived in CoMO for the 4 years I was SoS. Honestly prior to that I was only a marginal fan but 4 years in CoMO radicalized me 😂
Replying to @JasonKander
Not a true son you are Mr. kander.
1
4
89
22,660
rahul kapur retweeted
Congratulations to Secretary Hoskins on having avoided being detained for contempt by the Missouri Supreme Court by deciding to do his job and follow the law. Always good to see a fellow Missouri Secretary of State succeed!
31
102
2
1,782
31,718
rahul kapur retweeted
Atrial Fibrillation AMAZING . FINALLY *Losing weight does NOT decrease the risk of A fib *Obesity has NOT correlation with A fib CAFFEINE (COFFEE) does NOT INCREASE atrial fibrilllation
6
34
1
330
38,895
rahul kapur retweeted
Alpha -Gal syndrome Two years ago, we had not even heard of it now it's everywhere
6
7
145
32,615
rahul kapur retweeted
Taxi driver in New York asked me if I knew Stefanos Tsitsipas. I said, "We're very close." He said, "Good. Tell him to stop taking bathroom breaks like he's searching for Narnia." I pulled my hood up and pretended I was a tourist from Oslo.
538
1,684
248
38,248
2,215,499
rahul kapur retweeted
From the master - as often more pertinent questions than answers
Hi all, The Lp(a) HORIZON trial has released topline data and, quite shockingly, missed its primary endpoint. In other words, lowering Lp(a) in patients with prior MI, stroke or peripheral arterial disease, who were otherwise very well treated for LDL-C, blood pressure, diabetes and other risk factors, did not reduce the primary cardiovascular endpoint. We obviously need to see the full data before making firm conclusions, and I don’t want to speculate too much without the details. But this is a big enough result that it is worth summarizing what we know, what we don’t know, and what this may mean for our patients after 20+ years of trying to test the “Lp(a) hypothesis.” What we know: 1-There are hundreds if not thousands of genetic, epidemiologic and Mendelian-randomization studies showing that elevated Lp(a) is associated with MI, stroke, peripheral arterial disease and aortic stenosis. That body of evidence is very strong. 2-However, much of those data come from community-based populations, often before the era of intensive LDL-C lowering and modern secondary prevention. 3-There has been much less information about how much residual risk Lp(a) carries in someone who has already had an event and is then treated very aggressively. 4-HORIZON may have had some of the best-treated patients of any recent cardiovascular outcomes trial. Baseline LDL-C was about 65 mg/dL, a measured LDL-C contains the cholesterol carried on Lp(a), so in reality, 15-20 points lower. 5-In patients with very high Lp(a), if you correct LDL-C for Lp(a)-cholesterol, the actual LDL-C carried by LDL particles may have been closer to 45–50 mg/dL, perhaps even lower in some patients. 6-This raises a very basic question: Can you still demonstrate a major incremental benefit from lowering another apoB-containing particle when the underlying LDL burden has already been driven this low? What we don’t know: 1-What was the actual corrected LDL-C in these patients? I think it would be extremely informative to directly measure Lp(a)-C and calculate corrected LDL-C. This may tell us a lot about the biological setting in which pelacarsen was being tested. 2- What was the OxPL status? Our prior work has suggested that much of the pro-inflammatory biology associated with Lp(a) is related to its enrichment in oxidized phospholipids. Did OxPL fall? Did patients with higher OxPL derive more benefit? Was Lp(a) concentration actually identifying the patients with the most pathogenic particles? 3- Did we measure the right component of Lp(a) for trial inclusion? We generally measure molar particle concentration. But is molar concentration itself the main driver of risk, or is it partly a surrogate for what the particle carries? Cholesterol? Triglycerides? Oxidized phospholipids? Other proteins? Could two patients with the same Lp(a) concentration have very different Lp(a)-mediated risk? I think this question deserves much more attention. 3- Were the genetic data telling us exactly what we thought they were telling us? The genetic data are extremely compelling, but genetics reflect lifelong exposure. A clinical trial treats patients late in life, often after decades of arterial injury and after an event has already occurred. Those are not necessarily the same experiment. Could there also be some unrecognized biology linked to the LPA locus that we have not completely accounted for? That possibility should at least be considered. 3- Does very low LDL-C modify the Lp(a) risk relationship? Maybe Lp(a) is particularly important when LDL-C is higher, but its contribution becomes smaller once LDL-C is driven to very low levels. Again, we need the data. 4- Does aspirin or other antiplatelet therapy reduce part of the risk associated with Lp(a)? Lp(a) has potentially important prothrombotic effects. Almost everyone in a trial like HORIZON is receiving contemporary antiplatelet therapy. Could that blunt one component of the risk associated with Lp(a)? 5- Why are these patients still having events? This may be one of the most interesting questions of all. These are patients with LDL-C around 65 mg/dL, and perhaps corrected LDL-C substantially lower, yet cardiovascular events continue to occur. What is driving that residual risk? Inflammation? Thrombosis? Plaque burden that is already too advanced? Other lipoprotein characteristics? Something we are not measuring? 6- Do we need to re-examine some basic assumptions about atherosclerosis? We have spent decades focusing heavily on the quantity of circulating lipoproteins. But perhaps lipoproteins are relatively benign until they undergo biological modification in the artery wall. Oxidation may be one of those key modifications. For some patients, the answer may be to remove more particles from the circulation. For others, perhaps the better approach is to prevent their oxidation or block the downstream biological effects of oxidized lipids. The recent difficulties with anti-inflammatory approaches, including IL-6 inhibition, make these mechanistic questions even more interesting. 7- Was there something specific about pelacarsen, the degree or timing of Lp(a) lowering, advanced disease, trial duration, background therapy or patient selection that mitigated a potential benefit? We simply don’t know yet. That is why the detailed results will be so important. What does this mean for patients today? If you have already had an MI, stroke or PAD, the immediate lesson is very clear: 1- Get all of your established risk factors treated aggressively. 2- Get LDL-C/apoB very low. 3- Control blood pressure. 4- Control diabetes. 5- Don’t smoke. 6- Use appropriate antiplatelet and other guideline-directed therapies. HORIZON shows us what modern secondary prevention should look like. If you have elevated Lp(a) but have never had an event, the genetic and epidemiologic data still suggest increased lifetime risk. Until the other 4 outcome trials read out, I would continue to treat every modifiable risk factor aggressively. We should wait for those trials before drawing broad conclusions about the entire field. I think the story of Lp(a) therapy is beginning, not ending. We also need to show tremendous respect and gratitude to the patients who participated in HORIZON and to the investigators and companies that invested enormous resources to actually test the Lp(a) hypothesis, to the ultimate benefit to peole with elevated Lp(a) to best guide how to manage risk. More to come as we go forward.
3
4
1
100
41,008
Highly trained doctor who can recite the treatment for every strange helminth disease known to man makes less than manager at In n Out.
This infectious disease physician in Illinois made $150,000 last year. • $150,000 base • $0 bonus • 30-hour workweek • 2 weeks PTO • 4/5 job satisfaction Private practice. Twenty years of experience. That's $96/hour. The same rate as a first-year dentist on the platform. Two decades in. Would you take this deal?
42
22
5
513
58,754
rahul kapur retweeted
Shoutout to @esaagar for being so anti gambling Name and shame influencers taking $$$ from these companies as they spread degeneracy
11
8
2
288
15,435
rahul kapur retweeted
I get why some of my ICU colleagues prefer working nights; fewer rounds, less bureaucracy, and a tighter-knit team. But no matter how you justify it, the biological reality catches up to you: we’re dying one night shift at a time
22
31
10
414
42,081
rahul kapur retweeted
There’s a kind of silence that comes after you’ve been carrying too much for too long. Not because you have nothing to say, but because you no longer know who would understand.
1
3
30
1,490
rahul kapur retweeted
I finally have all 1.2 million raw image files from my latest mission to ISS! Here is a sample of one of my favorite Milky Way photos, taken from the Cupola with Nikon Z9, Arri Zeiss 15mm lens, T1.8 with custom sidereal drive that cancelled out star motion relative to our orbit.
1,512
13,355
970
105,697
7,476,535
rahul kapur retweeted
Incredible thread. Silver Fox drops a master class, I can't describe how generous this is, this is knowledge you'd normally have to pay thousands for And he just posted it
My takes on the 13 most popular anabolic compounds. Brief, direct, and no hype. This is all pulled from decades of running them, supervising clients run them, and reading, swimming, and living in the research, the anecdote, and the practical application. A thread 🧵👇
5
14
418
78,760
rahul kapur retweeted
now we're talking REAL things. these are the chats I want on my TL.
There is no evidence reincarnation is linear. Your next life could be thousands of years ago.
177
14,478
77
96,876
2,100,462